Supplemental Table 2.
Comparison of timing of COVID-19 with prevalence of primary and secondary endpoints among the subgroup of women with gestational diabetes mellitus
| Variable | n (GDM) | Diagnosis of COVID-19 before the diagnosis of GDM | Diagnosis of COVID-19 with or after the diagnosis of GDM | |
|---|---|---|---|---|
| Combined primary maternal endpoint (yes) | 138 | 2 (5.6) | 20 (19.6) | a |
| Combined primary fetal and neonatal endpoint (yes) | 126 | 8 (24.2) | 20 (21.5) | |
| Mother in ICU (yes) | 137 | 1 (2.8) | 13 (12.9) | |
| Maternal oxygen supplementation (yes) | 138 | 2 (5.6) | 17 (16.7) | |
| Maternal viral pneumonia (yes) | 136 | 2 (5.6) | 13 (13.0) | |
| Cesarean delivery (yes) | 130 | 17 (50.0) | 40 (41.7) | |
| Child in neonatal ICU (yes) | 124 | 25 (78.1) | 73 (79.4) | |
| Small for gestational age (yes) | 113 | 3 (9.7) | 6 (7.3) | |
| Large for gestational age (yes) | 113 | 7 (22.6) | 19 (23.2) |
Data are presented as number (percentage).
GDM, gestational diabetes mellitus; ICU, intensive care unit.
Kleinwechter. Gestational diabetes mellitus and COVID-19: COVID-19–Related Obstetric and Neonatal Outcome Study registry results. Am J Obstet Gynecol 2022.
a
P<.05 for comparison between the diagnosis of COVID-19 before the diagnosis of GDM and the diagnosis of COVID-19 with or after the diagnosis of GDM based on the chi-squared test or Fisher exact test.